Monitoring and actions carried out by Santé publique France
Santé publique France analyzes various data and conducts or contributes to several studies to document antibiotic use and antibiotic resistance in France.
Monitoring Antibiotic Use in Community Settings and Long-Term Care Facilities
Santé publique France analyzes data on antibiotic reimbursements from the national health insurance system available in the National Health Data System (SNDS). These analyses cover the entire outpatient sector as well as long-term care facilities (Ehpad) without an in-house pharmacy (PUI).
Santé publique France also publishes on the Odissé portal the number of antibiotic prescriptions and the number of doses, measured in defined daily doses (DDJ). A report is published annually on November 18, which is designated as Antibiotic Awareness Day.
The indicators are expressed per population and per day (per 1,000 inhabitants per day). They are broken down by sex, age group, region, department, EPCI, and for certain molecules or families of molecules.
The indicators are expressed in relation to the length of stay in nursing homes (per 1,000 days of nursing home care). They are broken down by sex, age group, region, and certain drugs or drug classes. The vast majority of nursing homes do not have an in-house pharmacy.
Monitoring of reports of healthcare-associated infections in healthcare facilities caused by drug-resistant bacteria
e-Sin is a digital application developed to monitor and prevent healthcare-associated infections in France.
Every five years, Santé publique France conducts prevalence surveys on healthcare-associated infections (ENP). These surveys cover French healthcare facilities—both public and private—and, in the following year, long-term care facilities (Ehpad).
These surveys cover all patients or residents present in the facility on a given day. They measure:
- the prevalence of healthcare-associated infections, including those associated with antibiotic-resistant bacteria,
- the prevalence of antimicrobial therapy.
They describe the main characteristics of infected and uninfected patients, as well as the specific operational features of the facilities. They provide an opportunity to engage all healthcare professionals and prescribers at participating facilities. They help identify priorities for action and ensure monitoring of prevention efforts and the appropriate use of antibiotics at the local, regional, and national levels.
The next survey will take place in 2028.
Learn more:
Raising awareness among healthcare professionals and the general public about antibiotic resistance through a “One Health” approach
From 2016 to 2025, Santé publique France coordinated the publication of a document compiling the latest French surveillance data on antibiotic resistance and antibiotic use in human health, animal health, and ecosystems. Starting in 2019, an overview of awareness-raising and prevention initiatives regarding antibiotic resistance in these three sectors was included, along with key international initiatives under the “One Health” approach.
Summaries to Download
- Preventing Antibiotic Resistance: A “One Health” Approach (November 21, 2023)
- Preventing Antibiotic Resistance: A “One Health” Approach (November 19, 2022)
- Antibiotics and Bacterial Resistance: Action Steps to Build on the Progress Made in 2020: A Synthesis of Surveillance Data from Humans, Animals, and the Environment (November 18, 2021)
- Antibiotics and Bacterial Resistance: Preventing a Respiratory Viral Infection Saves an Antibiotic! (November 18, 2020)
- Antibiotics and Bacterial Resistance: A Global Threat with Individual Consequences! Antibiotics and Bacterial Resistance: A Global Threat with Individual Consequences! (November 18, 2019)
- Antibiotic Use and Antibiotic Resistance in France: Preventing an Infection Saves an Antibiotic! (November 18, 2018)
- Antibiotic Use and Antibiotic Resistance in France: Let’s Take This Seriously, Let’s Be Responsible (November 18, 2017)
- Antibiotic Use and Antibiotic Resistance in France: The Need for Determined and Sustained Action (November 18, 2016)
- Antibiotic Use and Antibiotic Resistance in France: The Need for Determined and Sustained Action. Summary of Surveillance Data, November 18, 2015.
- Antibiotic Use and Antibiotic Resistance in France: The Need for Determined and Sustained Action. Summary of Surveillance Data, November 18, 2014.
See also
magazines/revues
20 November 2023
Weekly Epidemiological Bulletin, November 21, 2023, No. 22-23 Antibiotic Resistance in 2023: From Human Health Surveillance to a “One Health” Approach
EU-JAMRAI (European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections), a European joint action to combat antibiotic resistance and healthcare-associated infections. Its goal is to support the 30 partner countries in better coordinating their efforts and implementing more effective public health policies to combat antimicrobial resistance.
France is actively involved in this project and is one of the 130 European partners participating. Coordination is provided by Inserm (the French National Institute of Health and Medical Research) in collaboration with the Ministry of Health.
Santé publique France contributes to the work of EU-JAMRAI, as do several national agencies and national reference centers, primarily focusing on issues related to improving cross-analyses of surveillance data on antibiotic use and resistance across various sectors (human, animal, and environmental health), as well as promoting the proper use of antibiotics and preventing infections.
Launched in November 2021 and funded under the Priority Research Program (PPR) on Antibiotic Resistance, PROMISE brings together 120 partner members involved in the fight against antibiotic resistance in France within a One Health meta-network. PROMISE serves to foster collaboration among stakeholders who typically work in silos and enables network members to share their practices, expertise, and knowledge, as well as to coordinate their efforts.
Santé publique France and its direct partners—national agencies and national reference centers—contribute to the work of the PROMISE meta-network on the same issues as those addressed by EU-JAMRAI.
Other Projects
Santé publique France conducted the first assessment of the burden of antibiotic resistance in France. The “Burden BMR” study provided the first estimate of the number of infections and deaths caused by the main antibiotic-resistant bacteria in France.
Following this work, Santé publique France collaborated with the European Center for Disease Prevention and Control (ECDC) to estimate the burden of infections caused by antibiotic-resistant bacteria in Europe, both at the European level and by country
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modeling analysis | PubMed
- Assessing the health burden of infections with antibiotic-resistant bacteria in the EU/EEA, 2016–2020
Santé publique France also collaborated on the Druti study on antibiotic resistance in urinary tract infections diagnosed in primary care.
From 2019 to 2025, Santé publique France developed a social marketing campaign on the prevention of antibiotic resistance targeting healthcare professionals and the general public. This initiative was carried out in conjunction with the national Primo and Matis programs through the management of the Antibiomalin website.
- Learn more on the Antibiomalin website | Santé.fr